STERIS plc $STE Stock: McCollum Christoferson Group LLC Lowers Stake

13 Oct 2026, 17:21 by Mitch Edgeman · The Markets Daily

McCollum Christoferson Group LLC reduced its stake in STERIS plc (NYSE:STE – Free Report) by 7.8% during the third quarter, Holdings Channel.com reports. The fund owned 30,138 shares of the medical equipment provider’s stock after selling 2,535 shares during the period. STERIS makes up about 0.9% of McCollum Christoferson Group LLC’s portfolio, making the stock its 24th biggest position. McCollum Christoferson Group LLC’s holdings in STERIS were worth $6,329,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in STE. Western Wealth Management LLC bought a new position in STERIS during the 1st quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its stake in shares of STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 113 shares during the last quarter. Meramec Financial Planners LLC acquired a new stake in shares of STERIS during the first quarter worth $33,000. Trust Co. of Vermont acquired a new stake in shares of STERIS during the second quarter worth $41,000. Finally, CrossGen Wealth LLC bought a new position in STERIS during the fourth quarter worth $46,000. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Down 0.6%

Shares of STERIS stock traded down $1.26 during trading on Tuesday, reaching $217.72. 183,105 shares of the company traded hands, compared to its average volume of 763,620. The firm has a market capitalization of $21.23 billion, a PE ratio of 26.62 and a beta of 0.92. STERIS plc has a 1-year low of $195.14 and a 1-year high of $269.44. The company has a 50 day moving average price of $222.15 and a 200-day moving average price of $217.93. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.91 and a quick ratio of 1.35.

STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The business had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company posted $2.34 earnings per share. The business’s quarterly revenue was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. As a group, equities research analysts expect that STERIS plc will post 11.12 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Friday, September 4th were paid a $0.69 dividend. The ex-dividend date was Friday, September 4th. This represents a $2.76 annualized dividend and a dividend yield of 1.3%. This is a boost from STERIS’s previous quarterly dividend of $0.63. STERIS’s dividend payout ratio (DPR) is 33.74%.

Insider Activity at STERIS

In related news, Director Mohsen Sohi sold 4,058 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total value of $956,795.24. Following the completion of the sale, the director directly owned 24,305 shares of the company’s stock, valued at $5,730,632.90. The trade was a 14.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.12% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday. UBS Group lowered their price objective on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $271.33.

Get Our Latest Stock Report on STE

About STERIS

(Free Report)

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, surgical procedures, and the manufacture of healthcare and pharmaceutical products. The company serves healthcare providers, pharmaceutical and biotechnology manufacturers, and other organizations that require controlled, sterile environments.